A judge declines to stop the end of the tirzepatide shortage
Compounders asked a federal court to block the FDA’s decision that the tirzepatide shortage was over. The court said no, and the wind-down dates held.
Who feels it
-
Pharmacies
Rethink
State-licensed pharmacies had already passed their deadline; large outsourcing sites followed.
-
Sellers
Rethink
A clear loss for compounders and for clinics that sold their product.
-
Patients
Adjust
Compounded tirzepatide from a pharmacy became much harder to get after the deadlines.
-
Prescribers
Adjust
Plan the switch for patients on compounded tirzepatide before their supply runs out.
-
Payers
Worth knowing
Fewer cheap copies may push some members back to asking for coverage of the brand.
Background
When a drug is on the FDA shortage list, pharmacies may make copies of it. The FDA said in late 2024 that the tirzepatide shortage had ended, which started a countdown for compounders to stop.
The court’s answer
A group representing outsourcing facilities sued, saying the FDA had moved too fast. In March 2025 a federal judge declined to block the agency’s decision.
The dates that followed
- State-licensed compounding pharmacies had an earlier deadline in February.
- Larger outsourcing facilities had until 19 March 2025.
Who it hits
The ruling closed the main legal route for routine compounded tirzepatide. It also told the industry that the same path would likely fail for other GLP-1 drugs once their shortages ended.
Source US District Court for the Northern District of Texas, Outsourcing Facilities Association v. FDA, March 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
